On June 23, 2025, the Food and Drug Administration conferred accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adults with locally advanced or metastatic epiderm...
On June 18, 2025, the Food and Drug Administration sanctioned tafasitamab-cxix (Monjuvi, Incyte Corporation) in conjunction with lenalidomide and rituximab for adults with relapsed or refractory folli...
Introduction: What is the PiggyBac Transposon System? The PiggyBac transposon system is a non-viral gene delivery tool that enables the insertion of specific genes into host genomes. Originally discov...
Latest breakthroughs in the treatment of breast cancerBy 2025, the domain of advanced breast cancer treatment is swiftly transforming, providing renewed optimism to patients globally. Recent advanceme...
On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with advanced head and neck squamous cell carcinoma (HNSCC) that can be surgically removed and sh...
On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adults with recurring low-grade intermediate-risk non-muscle invasive bladder c...
On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a type of medicine that blocks certain enzymes, for people with advanced or spreading ROS1-posit...
On June 3, 2025, the Food and Drug Administration (FDA) sanctioned darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc.) for metastatic castration-sensitive prostate cancer (mCSPC). The FDA has...
IMPower133 study The IMpower133 study has brought significant advancements in the treatment of advanced-stage small-cell lung cancer (ES-SCLC). By combining atezolizumab, a type of immunotherapy, wit...
CAR T Cell therapy for gastric cancer The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting introduced an important new cancer treatment: Satricabtagene autoleucel (satri-cel), a CAR T...